Comparative efficacy of deferrioxamin and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients

Scientific Journal of Kurdistan University of Medical Sciences

Volumn 14, Issue 2, 2009, Pages 21-30

  Kompany, Farzad ^a   Mohammadi, Shilan ^a   Sigari, Naseh ^a   Hadizadeh, Nooshin ^a   Rezaie, Nazila ^a   Gharibi, Fardin ^a  

^a KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Deferiprone; Deferrioxamin; Echocardiographic indices; Major thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; AORTA ROOT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE; HEART VALVE; HUMAN; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

EID: 78049287248     PISSN: 1560652X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sunil G, Rohi S, Nishi M. Comparative efficacy of deferrioxamin, Deferiprone and in combination in iron chelation in thalassemic children. Indian pediatrics 2004; 41: 21-27.
2. Julian saulescu. Thalassemia major: the murkey story of defeiprone. BMJ 2004; 328: 358-359.
3. Ansari Sh, Vossogh P, Razavi MR, Nojoomi M. Assesment of cardiac complication and mortality rate of Beta thalassemia major in Hazrat Ali Asghar Hospital in past ten years. Iran medical university journal 1382; 36: 497-502.
4. th edition, oxford: black well science company, 2001, pp: 296-300.
5. Aureolio M, Geunaro. D. A, Alberto. M, Marcello C, Calogero C, Paolo C et al. Deferiprone versus Deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood cells, molecules and diseases 2002; 28: 196-208.
6. Hoffbond V. Deferiprone therapy for thalassemial iron overload. Best practice and research clinical hematology 2005; 18: 299-317.
7. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24.
8. th edition, Philadelphia, W.B Saunders company, 2002, pp: 912-930.
9. Pennell DJ, Berdoukas V, Karaqiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferouamine in beta-thalassemia major Patients with asymptomatic myocardial Siderosis. Blood 2006; 107: 3738-44.
10. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Aqus A, et al. Combined chelation therapy in thalssemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J cardiovase Magn Reson 2008; 10: 12.
11. Kolnagou A, Economides C, Eracleous E, kontoghiorghes GJ. Long term comparative studies in thalassemia Patients treated with deferoxamine or a deferouamine / deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008; 32: 41-7.
12. Noori N, Barbari T, Mottaghi H, Ariz A. Echocardiographic evaluation of Beta thalassemia patients. Zahedan Medical University Journal 2002; 45: 31-36.
13. Mohsenzadeh A, Namdari M, matin A. Cardiac diseases in Beta thalassemia Patients. Lorastan Medical university journal 2004; 20: 69-72.
14. Bijani Kh, Tamaddoni A, Ghadimi R, Hamzeh Pour R. Evaluation of pulmonary function in patients with Thalassemia major. Babol Medical University journal 2003; 1: 36-40.
15. Noori NM, Sohrevardi SR. Evaluation of Myocardial performance index (MPI) in Beta-Thalassemia jajor patients at the Ali Asghar Hospital, Zahedan, Iran. Zahedan Medical University Journal 2004; 21: 60-64.
16. Anderson LJ, Wonke N, Prescott E. Improved myocardial iron levels and ventricular function with oral deferiprone compared with subcutaneous desferrrioxamine in thalassemia. Lancet 2002; 360: 516-520.
17. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major. Haematology 2003; 70: 392-397.
18. Peng CT, Chow KC, Chen JH. Safety monitoring of cardiac and hepatic systems In B-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology 2003; 70: 392-397.
19. Antonis K, Vassilios L, Helen B, Nikolaos L. K, Efthymia A, Ioannis P, et al. Iron chelation treatment with combined therapy with deferiprone and Deferroxamine: A12 month trial. Blood cell,molecules and diseases 2006, 36: 21-25.
20. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess Cardiac IRON and the Prevention of heart disease in thalassemia The Protocol of the international committee on oral chelators Hemoglobin 2006; 30: 239-49.
21. El- Beshlawy A, Manz c, Naja M. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 2008; 87: 545-50.